Power supply issue at Mankind Pharma Sikkim facility, operations disrupted
New Delhi: Mankind Pharma has informed that operations at its manufacturing facility at Daring Block, Berimok, Namchi Zilla, South Sikkim have been disrupted due to disturbance in power/utility supply because of flash floods in river Teesta, since October 04, 2023. There is no major disruption expected in the supply chain as the manufacturing of the products have been diverted to...
New Delhi: Mankind Pharma has informed that operations at its manufacturing facility at Daring Block, Berimok, Namchi Zilla, South Sikkim have been disrupted due to disturbance in power/utility supply because of flash floods in river Teesta, since October 04, 2023. There is no major disruption expected in the supply chain as the manufacturing of the products have been diverted to other plants.
"The business operations of the Company continued as usual as the other plants are fully operational," the Company stated in a BSE filing.
There is no loss or harm caused to any personnel or property. All assets of the Company are adequately insured.
A flash flood in the Teesta River in Lachen Valley is the result of the cloud burst over Lhonak Lake in North Sikkim.
Read also: Mankind Pharma reports 66 percent jump in Q1 profit
Medical Dialogues team had reported that flash floods in the Teesta River had led to disruption in operations at Alembic Pharma's Sikkim-based manufacturing plant. "We would like to inform that due to flash floods in river Teesta because of cloud burst, water entered our manufacturing facility at Namthang, South Sikkim, and hence manufacturing operations stand disrupted with effect from October 4," the drug firm had said in a regulatory filing.
Read also: Flash floods in Teesta River: Alembic Pharma Sikkim plant manufacturing operations disrupted
Headquartered in Delhi, Mankind Pharma was founded in 1991 by R.C. Juneja. The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
Read also: Mankind Pharma success boosts hopes of more consumer IPOs in India
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd